Since the emergence of coronavirus disease 2019 (Covid-19) on December 2019, the number of confirmed and death cases are still increasing until now. Almost every nation around the world has been significantly impacted by Covid-19, starting from economic, health, and also social aspects. While some severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections appear as mild upper respiratory symptoms and may be self-limiting, there are still notable number of patients require hospitalizations and intensive treatment following progression into a more severe cases, varying from simple lower respiratory tract infections to acute respiratory distress syndrome (ARDS) and eventually may turn into multi-organ failure (MOF).
Cases’ severity from Covid-19 are varied among all age populations depending on their comorbidities. Several observational studies and meta-analyses have shown that underlying cardiovascular disease, diabetes mellitus, and hypertension clearly increase the severity and mortality of Covid-19. However, unlike diabetes and hypertension, relatively few studies have been conducted on dyslipidemia and obesity, two of the most important risk factors of cardiovascular disease. Several observational studies also have reported an association between high-density lipoprotein (HDL) cholesterol levels and the severity of Covid-19; however, the results are inconsistent. The role of underlying overweight and obesity into the course of Covid-19 is also still debatable. Not only comorbidities, the role of drugs commonly used in patients with dyslipidemia and obesity has gathered a lot of attention, because they may potentially alter the course of Covid-19. These metabolic-based approaches for Covid-19 may bring a better evidence into risk stratification and disease management strategies.
The goal of this Research Topic is to gather Original Research articles, Reviews, Discussions, and Correspondences which will improve our understanding about dyslipidemia, obesity and Covid-19 outcomes. More research regarding this topic is needed to build a comprehensive understanding and proper management strategies for people with dyslipidemia, obesity and its related disorders during Covid-19 pandemic. We hope that this Research Topic will bring a better evidence into Covid-19 risk stratifications and disease management.
We welcome submission of original research articles, review articles, discussions, and correspondences which address the topics of dyslipidemia (including its related disorders) and Covid-19 outcomes.
Welcome subtopics include (but are not limited to):
• Dyslipidemia (including its related disorders) and Covid-19 outcomes.
• Overweight, obesity (including body mass index) and Covid-19 outcomes.
• The role of lipid profiles (LDL, HDL, triglycerides) in predicting the Covid-19 outcomes.
• The role of lipid metabolism in pathophysiologic process of Covid-19.
• The impact of Covid-19 pandemic on different aspects (eg. social, mental health) of patients with dyslipidemia and obesity.
• The relationship between lipid altering drugs (eg. statin, metformin, GLP-1RA, etc.) with Covid-19 outcomes.
• Diet and nutritional-based approach for patients with dyslipidemia and obesity during Covid-19 pandemic.
Since the emergence of coronavirus disease 2019 (Covid-19) on December 2019, the number of confirmed and death cases are still increasing until now. Almost every nation around the world has been significantly impacted by Covid-19, starting from economic, health, and also social aspects. While some severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections appear as mild upper respiratory symptoms and may be self-limiting, there are still notable number of patients require hospitalizations and intensive treatment following progression into a more severe cases, varying from simple lower respiratory tract infections to acute respiratory distress syndrome (ARDS) and eventually may turn into multi-organ failure (MOF).
Cases’ severity from Covid-19 are varied among all age populations depending on their comorbidities. Several observational studies and meta-analyses have shown that underlying cardiovascular disease, diabetes mellitus, and hypertension clearly increase the severity and mortality of Covid-19. However, unlike diabetes and hypertension, relatively few studies have been conducted on dyslipidemia and obesity, two of the most important risk factors of cardiovascular disease. Several observational studies also have reported an association between high-density lipoprotein (HDL) cholesterol levels and the severity of Covid-19; however, the results are inconsistent. The role of underlying overweight and obesity into the course of Covid-19 is also still debatable. Not only comorbidities, the role of drugs commonly used in patients with dyslipidemia and obesity has gathered a lot of attention, because they may potentially alter the course of Covid-19. These metabolic-based approaches for Covid-19 may bring a better evidence into risk stratification and disease management strategies.
The goal of this Research Topic is to gather Original Research articles, Reviews, Discussions, and Correspondences which will improve our understanding about dyslipidemia, obesity and Covid-19 outcomes. More research regarding this topic is needed to build a comprehensive understanding and proper management strategies for people with dyslipidemia, obesity and its related disorders during Covid-19 pandemic. We hope that this Research Topic will bring a better evidence into Covid-19 risk stratifications and disease management.
We welcome submission of original research articles, review articles, discussions, and correspondences which address the topics of dyslipidemia (including its related disorders) and Covid-19 outcomes.
Welcome subtopics include (but are not limited to):
• Dyslipidemia (including its related disorders) and Covid-19 outcomes.
• Overweight, obesity (including body mass index) and Covid-19 outcomes.
• The role of lipid profiles (LDL, HDL, triglycerides) in predicting the Covid-19 outcomes.
• The role of lipid metabolism in pathophysiologic process of Covid-19.
• The impact of Covid-19 pandemic on different aspects (eg. social, mental health) of patients with dyslipidemia and obesity.
• The relationship between lipid altering drugs (eg. statin, metformin, GLP-1RA, etc.) with Covid-19 outcomes.
• Diet and nutritional-based approach for patients with dyslipidemia and obesity during Covid-19 pandemic.
